Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joep H M van Esch

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Expert Opinion on Investigational Drugs|February 22, 2012
Angiotensin II type 2 receptor agonists: where should they be applied?Koen Verdonk, A H Jan Danser, Joep H M van Esch
Circulation|October 25, 2006
Letter by Krop et al regarding article, "Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium"Manne Krop, Joep H M van Esch, A H Jan Danser
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 30, 2007
Prorenin and the (pro)renin receptor--an updateA H Jan Danser, Wendy W Batenburg, Joep H M van Esch
Hypertension (Dallas, Tex. : 1979)|August 25, 2010
On the origin of urinary angiotensin IIMieke van den Heuvel, Joep H M van Esch, A H Jan Danser
Journal of Molecular Medicine (Berlin, Germany)|March 7, 2008
Prorenin anno 2008A H Jan Danser, Wendy W Batenburg, Joep H M van Esch, et al.
Pharmacology & Therapeutics|April 21, 2011
The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implicationsEls Moltzer, Jeroen Essers, Joep H M van Esch, et al.
Hypertension (Dallas, Tex. : 1979)|December 23, 2009
Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilationEls Moltzer, Anna V A Verkuil, Richard van Veghel, et al.
European Journal of Pharmacology|May 31, 2008
Effects of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III the preferred ligand of the angiotensin AT2 receptor?Joep H M van Esch, Chantal R Oosterveer, Wendy W Batenburg, et al.
British Journal of Pharmacology|May 10, 2006
AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activationJoep H M van Esch, Martin P Schuijt, Jilani Sayed, et al.
Journal of Hypertension|August 15, 2009
Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspectsMariëtte Hw Kappers, Joep H M van Esch, Stefan Sleijfer, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Expert Opinion on Investigational Drugs|February 22, 2012
Angiotensin II type 2 receptor agonists: where should they be applied?Koen Verdonk, A H Jan Danser, Joep H M van Esch
Circulation|October 25, 2006
Letter by Krop et al regarding article, "Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium"Manne Krop, Joep H M van Esch, A H Jan Danser
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 30, 2007
Prorenin and the (pro)renin receptor--an updateA H Jan Danser, Wendy W Batenburg, Joep H M van Esch
Hypertension (Dallas, Tex. : 1979)|August 25, 2010
On the origin of urinary angiotensin IIMieke van den Heuvel, Joep H M van Esch, A H Jan Danser
Journal of Molecular Medicine (Berlin, Germany)|March 7, 2008
Prorenin anno 2008A H Jan Danser, Wendy W Batenburg, Joep H M van Esch, et al.
Pharmacology & Therapeutics|April 21, 2011
The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implicationsEls Moltzer, Jeroen Essers, Joep H M van Esch, et al.
Hypertension (Dallas, Tex. : 1979)|December 23, 2009
Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilationEls Moltzer, Anna V A Verkuil, Richard van Veghel, et al.
European Journal of Pharmacology|May 31, 2008
Effects of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III the preferred ligand of the angiotensin AT2 receptor?Joep H M van Esch, Chantal R Oosterveer, Wendy W Batenburg, et al.
British Journal of Pharmacology|May 10, 2006
AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activationJoep H M van Esch, Martin P Schuijt, Jilani Sayed, et al.
Journal of Hypertension|August 15, 2009
Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspectsMariëtte Hw Kappers, Joep H M van Esch, Stefan Sleijfer, et al.
Pageof 4